Sports Medicine

Presentation of Twelve Month Pilot Trial Data of Cytori® Cell Therapy™ for ACL Reconstruction

SAN DIEGO–(BUSINESS WIRE)–Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today Dr. Ramón Cugat MD, Ph.D. will present 12-month follow-up results from a 20-patient, single arm, open label pilot study on the use of Cytori Cell Therapy in anterior cruciate ligament (ACL) reconstruction. The presentation is titled ‘Biological Augmentation of ACL Reconstruction’ and will be made to The Orthobiologic Institute (TOBI) 7th Annual PRP and Regenerative Medicine Symposium in Las Vegas on June 10, 2016.

Patients in the study had sports-related injuries leading to complete rupture of their ACL, a relatively common sports injury that can impact the long-term careers of professional athletes as well as the ability of non-professional athletes to participate in active lifestyles. All patients in the study received Cytori Cell Therapy as an adjunct to bone-patellar tendon-bone grafting to reconstruct the ACL. Data to be presented include safety, feasibility, patient-reported outcomes related to activity levels and pain as well as serial magnetic resonance imaging (MRI) of the knee through one year. Data have been compared to a historical control group of similar patients treated at the same center by the same surgical team using the same procedure without supplementation with Cytori Cell Therapy.

Dr. Ramón Cugat is internationally-recognized for his expertise in orthopedics, sports medicine and the treatment of orthopedic trauma in elite soccer players. He is currently President of the Medical Council at the Catalan Mutual Insurance of Football under the Royal Spanish Football Federation and a recent inductee as a full academician into the Royal European Academy of Doctors. In addition, he is currently Co-Director of the Department of Orthopaedic Surgery and Traumatology at the Hospital Quiron in Barcelona, Spain and on the faculty of the Department of Surgery and Regenerative Medicine at the Universidad CEU Cardenal Herrera in Valencia, Spain. He has published more than 100 papers and multiple book chapters.

About Cytori
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information visit

Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including statements regarding conduct and results of investigator-initiated trials, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties are described under the heading “Risk Factors” in Cytori’s Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.


Cytori Therapeutics, Inc.
Tiago Girao, +1-858-458-0900

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button